Advertising by academic medical centers

Archives of Internal Medicine

Volumn 165, Issue 6, 2005, Pages 645-651

  Larson, Robin J ^a   Schwartz, Lisa M ^b   Woloshin, Steven ^b   Welch, H Gilbert ^b  

^a VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ARTICLE; CLINICAL RESEARCH; HEALTH PROMOTION; HEALTH SERVICE; PATIENT CARE; PRIORITY JOURNAL; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADVERTISING; HUMANS; INTERVIEWS; UNITED STATES;

EID: 15344351528     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.6.645     Document Type: Article

References (35)

1. Envisioning the Future of Academic Health Centers: Final Report of the Commonwealth Fund Task Force on Academic Health Centers. New York, NY: Commonwealth Fund; 2003.
2. AAMC Office of Governmental Relations. Medicare Disproportionate Share (DSH) payments. Available at: http://www.aamc.org/advocacy/libraryrteachhosp/ hosp0003 .htm. Accessed October 7, 2004.
3. Blumenthal D, Weissman JS, Griner PF. Academic health centers on the front lines: survival strategies in highly competitive markets. Acad Med. 1999;74: 1038-1049.
4. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet. 2001; 358:1141-1146.
5. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising, 1989-1998: a content analysis of conditions, targets, inducements, and appeals. J Fam Pract. 2000;49:329-335.
6. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med. 1999;14:651-657.
7. Sumpradit N, Fors SW, McCormick L. Consumers' attitudes and behavior toward prescription drug advertising. Am J Health Behav. 2002;26:68-75.
8. Hollon MF. Direct-to-consumer marketing of prescription drugs: creating consumer demand. JAMA. 1999;281:382-384.
9. Bell RA, Wilkes MS, Kravitz RL. Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. J Fam Pract. 1999;48:446-452.
10. Davis JJ. Riskier than we think? the relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs. J Health Commun. 2000;5:349-369.
11. Stewart KA, Neumann PJ. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation. Value Health. 2002;5:389-396.
12. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust. 2002;177:291-293.
13. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.
14. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA. 2002;288:1762-1767.
15. Hull SC, Prasad K. Reading between the lines: direct-to-consumer advertising of genetic testing in the USA. Reprod Health Matters. 2001;9:44-48.
16. Kessler DA, Pines WL. The federal regulation of prescription drug advertising and promotion. JAMA. 1990;264:2409-2415.
17. Wolfe SM. Direct-to-consumer advertising: education or emotion promotion [erratum appears in N Engl J Med. 2002;346:1424]? N Engl J Med. 2002;346: 524-526.
18. Wolfe SM. Direct-to-consumer advertising: education or emotion promotion [erratum appears in N Engl J Med. 2002;346:1424]? N Engl J Med. 2002;346: 524-526.
19. Holmer AF. Direct-to-consumer advertising: strengthening our health care system [comment]. N Engl J Med. 2002;346:526-528.
20. Drazen JM. The consumer and the learned intermediary in health care [comment]. N Engl J Med. 2002;346:523-524.
21. Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. N Engl J Med. 2002;346:529-531.
22. America's best hospitals. US News World Rep. July 22, 2002;133:44-46.
23. Comarow A. Best hospitals: methodology. US News World Rep. Available at: www .usnews.com/usnews/nycu/health/hosptl/methodology.htm. Accessed March 11, 2003.
24. National Opinion Research Center. U.S. News & World Report's annual ranking of America's best hospitals. Available at: http://www.norc.org/issues/ besthospitals .asp. Accessed March 11, 2003.
25. Larson RJ, Schwartz LM, Woloshin S, Welch HG. Data collection instrument. Available at: http://www.vaoutcomes.org/research_tools.php. Accessed November 18, 2004.
26. Audit Bureau of Circulations. Access ABC Newspapers Zip Breakout File. Schaumburg, III: Audit Bureau of Circulations; 2002.
27. Protecting human research subjects: IRB guidebook. Available at: http://ohrp .osophs.dhhs.gov/irb/irb_chapter4.htm. Accessed March 11, 2003.
28. Food and Drug Administration. Guidance for institutional review boards and clinical investigators: 1998 update. Available at: http://www.fda.gov/oc/ ohrt/irbs/toc4 .html#recruiting. Accessed March 11, 2003.
29. Blumenthal D, Campbell EG, Weissman JS. The social missions of academic health centers. N Engl J Med. 1997;337:1550-1553.
30. Griner PF, Blumenthal D. Reforming the structure and management of academic medical centers: case studies of ten institutions. Acad Med. 1998;73: 818-825.
31. Longo B, Paris B. Questions of ethics and performance arise for medical marketers in the 1990s. J Hosp Mark. 1991;6:29-35.
32. Fisher ES, Welch HG. Avoiding the unintended consequences of growth in medical care: how might more be worse? JAMA. 1999;281:446-453.
33. Black WC. Advances in radiology and the real versus apparent effects of early diagnosis. Eur J Radiol. 1998;27:116-122.
34. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending, part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138:273-287.
35. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending, part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138:288-298.